VivoSeq
Other

Stuttering

6

Pipeline Programs↗

3

Active Trials↗

6

Companies Involved↗

Stuttering is an early-stage landscape with 6 programs across 6 companies. The most active players are Otsuka, Endo Pharmaceuticals, Emalex Biosciences Inc.. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

11/100

Mech. Concentration

25/100

Completion Rate

80/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Otsuka logo

Otsuka

1 program

Phase 1Endo Pharmaceuticals logo

Endo Pharmaceuticals

1 program

Phase 2E

Emalex Biosciences Inc.

1 program

Phase 2COMPASS Pathways logo

COMPASS Pathways

1 program

Phase 2V

Viking Therapeutics, Inc.

1 program

Phase 3AbbVie logo

AbbVie

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

10

clinical trials

Completed4 · 40%
Unknown status2 · 20%
Recruiting1 · 10%
Suspended1 · 10%
Active, not recruiting1 · 10%
Not yet recruiting1 · 10%

Clinical Trials

Trial Activity

10 trials

Dopamine and Sensorimotor Function in Stuttering
Recruiting·UUniversity of California, San Francisco·Phase 1·NCT07215884·40 enrolled
Explorative Study for Treating Persistent Developmental Stuttering With Ramipril
Active, not recruiting·HHaEmek Medical Center, Israel·Phase 3·NCT04173949·10 enrolled
Noninvasive Thalamocortical Neuromodulation With Low-Intensity Focused Ultrasound for Persistent Developmental Stuttering
Not yet recruiting·UUniversity of Michigan·Preclinical·NCT07668882·20 enrolled
EXPRESS: Examining Pagoclone for Persistent Developmental Stuttering Study
Completed·Endo Pharmaceuticals logoEndo Pharmaceuticals·Phase 2·NCT00216255·120 enrolled
Safety and Efficacy Study of the Investigational Drug Pagoclone, in the Treatment of Persistent Developmental Stuttering (PDS)
Completed·PPharmacology Research Institute·Phase 2·NCT00239915
Effects of Ecopipam or Placebo in Adults With Stuttering (Speak Freely)
Completed·EEmalex Biosciences Inc.·Phase 2·NCT04492956·68 enrolled
A Study to Assess the Efficacy and Safety of Pagoclone for Adults With Stuttering
Completed·Endo Pharmaceuticals logoEndo Pharmaceuticals·Phase 2/3·NCT00830154·321 enrolled
A Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Asenapine With Flexible Dosing From 5mg to 20mg in Adults With Developmental Stuttering
Suspended·UUniversity of California, Irvine·Phase 3·NCT01684657·32 enrolled
Efficacy and Tolerability of Ecopipam in Adults With Childhood Onset Fluency Disorder (Stuttering).
Unknown status·GGerald Maguire, MD·Phase 2/3·NCT02909088·10 enrolled
Comparative Study Between Three Different Methods for Stuttering Therapy in Children
Unknown status·SSohag University·Phase 4·NCT05291572·30 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)